



SUPPLEMENTARY DATA

Supplementary Figure 1. Patient disposition.



SUPPLEMENTARY DATA

**Supplementary Figure 2.** Effect on HOMA-B at Week 24 with lixisenatide morning once-daily regimen, lixisenatide evening once-daily regimen and placebo. Data are LS mean ( $\pm$  SE) change from baseline. Mean ( $\pm$  SD) baseline HOMA-B values were 43.0 (33.2) (lixisenatide morning; n=255), 45.5 (42.8) (lixisenatide evening; n=255) and 41.7 (42.9) (placebo combined; n=170). LS mean difference ( $\pm$  SE) versus placebo at Week 24: 12.1 (3.28) [95% CI: 5.69, 18.56], p=0.0002 (morning) and 9.0 [95% CI: 2.45, 15.48], p=0.0071 (evening).



HOMA-B= homeostasis model assessment-B; LS=least squares; SE=standard error; SD=standard deviation.